Dr. David H. Kerman, MD

Dr. Kerman practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Kerman's NPI, 1851593040, was assigned on June 1, 2007. Dr. Kerman graduated from McGovern Medical School in 2001. Dr. Kerman holds Florida license ME 101537.

Dr. Kerman's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Kerman's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Kerman is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Kerman to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kerman practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Kerman's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Kerman is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Kerman's licenses on file in 2 states: Florida and Illinois.

Dmand AI lists acid reflux, acute gastroduodenitis, chronic inflammatory bowel disease (IBD), colonoscopy, gastroenteritis, hemorrhoids, irritable bowel syndrome (IBS) and upper GI endoscopy among the conditions Dr. Kerman treats.

CMS data shows 234 Medicare services from Dr. Kerman across 7 procedure codes in 2024, for 190 Medicare patients. Medicare paid $17,819 for them.

CMS counts 190 Medicare patients who saw Dr. Kerman in 2024. The largest group is 65 to 74, with 85 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 34% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kerman's median patient age at 55, with 46% women.

In 2024, Dr. Kerman wrote 535 Medicare Part D claims for 175 patients. 70% of them were for generic drugs. CMS names the drug for 350 of them, across 12 drugs with 11 or more claims each, at $1,842,983 in total drug cost. In 2023, CMS named 380 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Kerman for performance year 2024, reported as part of a group. Dr. Kerman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kerman as offering telehealth. CMS counts 66 procedures of colonoscopy by Dr. Kerman, more than 70% of the clinicians it reports for that procedure.

Dmand AI links 37 papers to Dr. Kerman, published from 2016 to 2025. 2020 was the busiest year, with 4. The most frequent topics are Crohn Disease, Inflammatory Bowel Diseases and Colitis, Ulcerative. Dr. Kerman has published most often in Clin Gastroenterol Hepatol. Dr. Kerman's most frequent co-authors are Maria Teresa Abreu, MD, Amar R. Deshpande, MD and Oriana Mazorra Damas, MD.

Dmand AI links Dr. Kerman to 6 clinical trials, 2 of them phase 1 studies. Conditions studied include Colitis, Ulcerative, Colitis and Crohn Disease. Shire sponsors the most, 3.

CMS Open Payments shows 40 general payments to Dr. Kerman from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 93% of the total. Ferring Pharmaceuticals Inc. paid the most, $14,389. It also lists 18 research payments totaling $1,682 from 2018 to 2019.

Dmand AI lists 1 award for Dr. Kerman, most recently CMS Stage 1 EHR in 2012.

Dr. Kerman graduated from McGovern Medical School in 2001.

Dr. Kerman is in network with 12 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.